Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70386 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 07.06.2026. Verfasst von Chan Y Cheah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology Sir Charles Gairdner Hospital Perth Australia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Roche, AbbVie.
Abstract (Originalsprache)
Follicular lymphoma (FL) is the most common indolent lymphoma. Although chemoimmunotherapy is effective, toxicity remains problematic, and novel treatments are required. We performed a Phase Ib/II study of obinutuzumab, lenalidomide, and venetoclax in patients with treatment‐naïve, high tumor burden, advanced‐stage FL. During induction (6 × 28‐day cycles), patients received obinutuzumab and venetoclax (in four dose levels from 400 mg day [D]1–10 to 800 mg daily) from Cycles 1 to 6 and lenalidomide (20 mg Days 1–21) from Cycles 2 to 6. Patients with complete response (CR) received 2 years maintenance obinutuzumab, while partial responders received 2 years obinutuzumab plus 6 months of venetoclax and lenalidomide. Genomic characterization and measurable residual disease (MRD) monitoring were performed using targeted next‐generation sequencing (NGS) by circulating tumor DNA (ctDNA). Fifty patients were enrolled with a median age 60. No maximum tolerated dose was defined, and the Phase II dose of venetoclax was 800 mg daily. The CR rate and objective response rate were 86% and 92%, respectively. At median follow‐up of 18.3 months, the 2‐year progression‐free survival and overall survival rates were 92% and 100%, respectively. The most common any‐grade adverse events were neutropenia (72%), diarrhea (52%), and upper respiratory infection (48%). Undetectable MRD after one cycle of therapy had a 95% negative predictive value for relapse, while detectable MRD after three cycles of therapy had a 75% positive predictive value. Obinutuzumab, lenalidomide, and venetoclax are active in patients with treatment‐naïve high tumor burden FL; however, myelosuppression impacted deliverability. ctDNA MRD is a promising biomarker in FL.
Autor:innen und Institutionen
- Department of Haematology Sir Charles Gairdner Hospital Perth Australia.
- Medical School University of Western Australia Perth Australia.
- Department of Haematology Peter MacCallum Cancer Centre and the Royal Melbourne Hospital Melbourne Australia.
- Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Australia.
- Department of Haematology Westmead Hospital Sydney Australia.
- Department of Haematology Townsville University Hospital Townsville Australia.
ORCID-Profile: Chan Y Cheah, Piers Blombery
Förderung
- Bristol-Myers Squibb
- Roche
- AbbVie
Zitieren
APA
Cheah, C. Y., Blombery, P., Johnston, A., Wight, J., Lewis, K. L., Bennett, R., Xie, J., Vlachos, S., Hunter, S. M., Gonzales, J., Binks, S., & Seymour, J. F. (2026). Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70386
Vancouver
Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, et al. Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. HemaSphere. 2026;10(6). doi:10.1002/hem3.70386
BibTeX
@article{Cheah2026,
author = {Cheah, Chan Y and Blombery, Piers and Johnston, Amanda and Wight, Joel and Lewis, Katharine L and Bennett, Rory and Xie, Jing and Vlachos, Stella and Hunter, Sally M and Gonzales, Joyce and Binks, Sally and Seymour, John F},
title = {Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70386}
}
EUVIMED